Log in
Enquire now
‌

US Patent 8067434 Compounds and methods for development of Ret modulators

Patent 8067434 was granted and assigned to Plexxikon Inc. on November, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Plexxikon Inc.
Plexxikon Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8067434
Date of Patent
November 29, 2011
Patent Application Number
12082665
Date Filed
April 11, 2008
Patent Citations Received
‌
US Patent 11851434 Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
0
‌
US Patent 12076322 Compounds and methods for kinase modulation, and indications therefor
0
‌
US Patent 11998545 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
0
‌
US Patent 11964988 Fused heterocyclic compounds as RET kinase inhibitors
0
Patent Primary Examiner
‌
D M Seaman
Patent abstract

Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8067434 Compounds and methods for development of Ret modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.